The company develops novel therapies for bile duct cancer, also called cholangiocarcinoma (CCA). This is done by employing a multidisciplinary approach to developing completely personalised cures. Our technology includes drug repurposing and innovation on new medical substances, diagnostics and methodology. Our goal is to quickly identify effective treatment using evidence-based tests using the patients own living cancer cells. Our evidence-based novel approach to matching living cancer cell response to genetic profile of individual patients could provide cost effective and efficacious therapy for each patient and reduction of healthcare costs of uneeded side effect. Sealds’s holistic approach is unique with possible modes of action that can be used on other solid cancers.
Together with our research partners the Institute of Cancer Research, The Radium Hospital, the Norwegian Centre for Molecular Medicine (University of Oslo, UiO), the Bioinformatics Core Facility (OUS) and Drug Discovery Laboratory AS, we have performed feasibility studies on living CCA cells donated by the Mayo Clinic, Harvard Medical School and the PSC Centre, UiO.
In our pilot, the living cells were treated with several hundred different medicines and sequenced. Several substances in our S-series appear to be very potent inhibitors in several CCA cell lines. Some of these substances have not previously been used in the treatment of CCA. Preliminary studies indicate that some of these findings are new, and we have an ongoing focus on developing patents, both on single agents as drug repurposing and on new combinations.
Clinical development will be conducted in collaboration with both Norwegian and American clinical research centres. These trials will be conducted at the Clinical Cancer Research Unit (Phase I unit) at the Norwegian Radium Hospital/Oslo University Hospital. The observational study is planned to commence in 2019.